siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53

Cell Biology International

Volumn 31, Issue 2, 2007, Pages 156-164

  Niu, Jian ^a   Xu, Zonghua ^b   Li, Xiang nong ^a   Han, Zeguang ^c  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Apoptosis; Chemosensitivity; IGF1R; Liver cancer; P53; siRNA

Indexed keywords

DOXORUBICIN; MESSENGER RNA; PROCASPASE 3; PROTEIN P53; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ASSAY; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; LIVER CANCER; MUTATION; NICK END LABELING; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR UPREGULATION; REDUCTION KINETICS; TREATMENT RESPONSE; WILD TYPE;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LIVER NEOPLASMS; MUTANT PROTEINS; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846625909     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2006.09.021     Document Type: Article

References (40)

1. Aden D.P., Fogel A., Plotkin S., Damjanov I., and Knowles B.B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282 (1979) 615-616
2. Ambrose D., Resnicoff M., Coppola D., Sell C., Miura C., Jameson S., et al. Growth regulation of human glioblastoma T98G cells by insulin-like growth factor-1 and its receptor. J Cell Physiol 159 (1994) 92-100
3. Andrews D.W., Resnicoff M., and Flanders A.E. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19 (2001) 2189-2200
4. Aplen N.J., Parrish S., Imani F., Fire A., and Morgan R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 98 (2001) 9742-9747
5. Ass B.L. Double-stranded RNA as a template for gene silencing. Cell 101 (2001) 235-238
6. Belfiore A., Pandini G., Vella V., Squatrito S., and Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 81 (1999) 403-407
7. Blum G., Gazit A., and Levitzki A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39 (2000) 15705-15712
8. Coppola D., Ferber A., Miura M., Sell C.D., Ambrosio C., Rubin R., et al. A functional IGF1 receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 14 (1994) 4588-4595
9. De Angelis, Ferber T., and Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J Cell Physiol 164 (1995) 214-221
10. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 411 (2001) 494-498
11. Erner H., Karnieli E., Rauscher F.J., and Le Roith D. Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93 (1996) 8318-8323
12. Girnita L., Girnita A., Brodin B., Xie Y., Nilsson G., Dricu A., et al. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 60 (2000) 5278-5283
13. Hakam A., Yeatman T.J., Lu L., Mora L., Marcet G., Nicosia S.V., et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30 (1999) 1128-1133
14. Hellawell G.O., Ferguson D.J., Brewster S.F., and Macaulay V.M. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 91 (2003) 271-277
15. Honda R. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420 (1997) 25-27
16. Jiang Y., Rom W.N., Yie T.A., Chi C.X., and Tchou-Wong K.M. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 28 (1999) 6071-6077
17. Juven Gershon T., and Oren M. Mdm2: the ups and downs. Mol Med 5 (1999) 71-83
18. Kamijo T. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95 (1998) 8292-8297
19. Kubbutat M.H. Analysis of the degradation function of Mdm2. Cell Growth Differ 10 (1999) 87-92
20. Lee C.T., Park K.H., and Adachi Y. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 10 (2003) 57-63
21. Le Roith D., Baserga R., Helman L., and Roberts C.T. Insulin-like growth factors and cancer. Ann Intern Med 122 (1995) 54-59
22. Li S.L., Liang S.J., Guo N., Wu A.M., and Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol Immunother 49 (2000) 243-252
23. Mamula P.W., and Goldfine I.D. Cloning and characterization of the human insulin-like growth factor 1 receptor gene 5′-flanking region. DNA Cell Biol 11 (1992) 43-50
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
25. Nakabayashi H., Taketa K., Miyano K., Yamane T., and Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42 (1982) 3858-3863
26. Neuenschwander S., Roberts C.T., and Le Roith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 136 (1995) 4298-4303
27. Pandini G., Vigneri R., Costantino A., Frasca F., Ippolito A., Fujita-Yamaguchi Y., et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5 (1999) 1935-1944
28. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B.A., Wernicke D., and Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53 (1993) 1102-1106
29. Sell C., Rubini M., Rubin R., Liu J.P., Efstratiadis A., and Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblast lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90 (1993) 11217-11221
30. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., De Angelis T., et al. Effect of a null mutation of the type 1 IGF receptor gene on growth and transformation of mouse embryo fibroblast. Mol Cell Biol 14 (1994) 3604-3612
31. Steinbach J.P., Eisenmann C., Klumpp A., and Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem Biophys Res Commun 321 (2004) 524-530
32. Tao W., and Levine A.J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Mdm2-mediated degradation of p53. Proc Natl Acad Sci USA 96 (1999) 3077-3080
33. Tao W., and Levine A.J. P19 (ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96 (1999) 6937-6941
34. Tezuka M., Watanabe H., Nakamura S., Yu D., Aung W., Sasaki T., et al. Antiapoptotic activity is dispensable for insulin-like growth factor I receptor-mediated clonogenic radioresistance after γ-Irradiation. Clin Cancer Res 7 (2001) 3206-3214
35. Trojan J., Johnson T.R., Rudin S.D., Tykocinski M., and Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science (Washington DC) 259 (1993) 94-97
36. Valentinis B., and Baserga R. IGF-I receptor signaling in transformation and differentiation. Mol Pathol 54 (2001) 133-137
37. Werner H., Karnieli E., Rauscher F.J., and LeRoith D. Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93 (1996) 8318-8323
38. Xie Y., Skytting B., Nilsson G., Brodin B., and Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 59 (1999) 3588-3591
39. Yee D. Are the insulin-like growth factors relevant to cancer?. Growth Horm IGF Res 11 (2001) 339-345
40. Yu H., and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92 (2000) 1472-1489